Učitavanje...
Metabolic reprogramming by N‐acetyl‐seryl‐aspartyl‐lysyl‐proline protects against diabetic kidney disease
BACKGROUND AND PURPOSE: ACE inhibitors (ACEIs) and AT(1) receptor antagonists (ARBs) are first‐line drugs that are believed to reduce the progression of end‐stage renal disease in diabetic patients. Differences in the effects of ACEIs and ARBs are not well studied and the mechanisms responsible are...
Spremljeno u:
| Izdano u: | Br J Pharmacol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7393199/ https://ncbi.nlm.nih.gov/pubmed/32352559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15087 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|